Showing posts with label OTC. Show all posts
Showing posts with label OTC. Show all posts

Tuesday, 3 September 2013

Axxess Pharma Inc to Acquire Canadian OTC Healthcare Company

Axxess Pharma Inc a specialty pharmaceutical and nutritional supplements company, today announced an Agreement in Principle to acquire a leading Canadian OTC healthcare company. Upon completion of the acquisition, the company will bring current sales and a valuable IP portfolio to Axxess Pharma. 

Monday, 1 July 2013

Elder Pharma acquires OTC business in the United Kingdom

The UK arm of Elder Pharmaceuticals - NutraHealth Ltd has acquired West Yorkshire-based firm Max Healthcare Ltd. The objective of the acquisition is in to re-enter over-the-counter  pharmaceutical business in the UK. Max Healthcare is an OTC business, which owns a range of marketing authorisations and provides own label and branded OTC medicines and products to a broad range of customers.

The acquisition will help in extending and enhancing the company's OTC product range, it added.

Max Healthcare is predominantly an outsourced operation with most of its manufacturing taking place in India



Enter your email address: Delivered by FeedBurner

Sunday, 24 February 2013

Reckitt Benckiser buys Chinese company Golong Medicine of Anhui

Reckitt Benckiser, a British maker of OTC drugs and home products, has bought Golong Medicine of Anhui, a TCM company known for its sore-throat treatment Man Yan Shu Ning. The British company wants to expand its distribution foothold in China as a way to increase revenues from its extensive list of products. It does not intend to take Man Yan Shu Ning to the west. Financial details of the transaction were not disclosed.

Friday, 18 January 2013

Sanjiu Medical acquires Guilin Tianhe ( Patch Manufacturer) for $94 million

China Resources Sanjiu Medical & Pharmaceutical has acquired a 97% interest in Guilin Tianhe Pharmaceutical Co., Ltd. Guilin Tianhe manufactures OTC patch products based on Traditional Chinese medicines. These patches are intended to treat  orthopedic conditions, provide pain relief, lessen allergy problems or address other disorders.
The purchase price was estimated to be 583 million RMB ($94 million).